We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
75 hedge funds and large institutions have $180M invested in Crescent Biopharma in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
185% more call options, than puts
Call options by funds: $94K | Put options by funds: $33K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 19
0.08% less ownership
Funds ownership: 1.04% → 0.96% (-0.08%)
4% less funds holding
Funds holding: 78 → 75 (-3)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
66% less capital invested
Capital invested by funds: $535M → $180M (-$356M)
Holders
75
Holders Change
-3
Holders Change %
-3.85%
% of All Funds
1.64%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
22
Increased
19
Reduced
19
Closed
25
Calls
$94K
Puts
$33K
Net Calls
+$61K
Net Calls Change
+$1.44M
Top Buyers
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$20.5M |
| 4 |
Jennison Associates
New York
|
-$16.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$13.1M |
